Bivalirudin Monitoring in Pediatric Ventricular Assist Device and Extracorporeal Membrane Oxygenation: Analysis of Single-Center Retrospective Cohort Data 2018-2022
Engel ER, Perry T, Block M, Palumbo JS, Lorts A, Luchtman-Jones L (2024) · Pediatric Critical Care Medicine · n=22
Study Profile
- Design
- single-center retrospective laboratory validation study (Cincinnati Children's Hospital Medical Center, 2018-2022) - 115 VAD samples and 105 ECMO samples assessed
- Sample size (n)
- 22
- Intervention
- Bivalirudin-calibrated dilute thrombin time (Bival dTT) assay for anticoagulation monitoring in pediatric VAD and ECMO
- Comparator
- Standard activated partial thromboplastin time (aPTT) assay
- Primary endpoint
- Correlation between Bival dTT, dTT, and aPTT vs bivalirudin plasma concentrations
- Primary result
- Bival dTT excellent correlation with dTT (R²=0.86-0.87) and anti-IIa (R²=0.94); aPTT correlated poorly (R²=0.004-0.1); Bival dTT validated for clinical use
- Follow-up duration
- VAD/ECMO support duration
- PMID
- 38713010
Key Findings
- aPTT correlates poorly with bivalirudin anticoagulant effect (R²=0.004-0.1)
- Bival dTT and dTT show excellent correlation with anti-IIa (R²=0.86-0.94)
- Provides validated alternative to aPTT for pediatric MCS monitoring
- Single institution can validate and clinically implement
- Opportunity for inter-institutional standardization
Limitations
- Single-center retrospective design
- Small patient cohort (n=22)
- No correlation with clinical outcomes yet established
- Therapeutic range still requires determination
- Not applicable to whole-leech hirudotherapy
Clinical Implications
Engel 2024 addresses a critical laboratory monitoring gap for bivalirudin in pediatric mechanical circulatory support. For ASH, this work demonstrates the technical infrastructure required to safely deploy the synthetic thrombin inhibitor pharmaceutical pathway - sophisticated assays, single-institution validation, inter-institution standardization - structurally separate from the K040187 device-leech US clinical practice which requires no such monitoring infrastructure.
Related Trials
Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation
McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)
Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021)
Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation
Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022)
Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023)